Antimicrobial Dressing Versus Standard Dressing in Obese Women Undergoing Cesarean Delivery

Subjects requiring cesarean delivery and without exclusion criteria will be informed by the
obstetrical team about the study and asked for permission to contact the study personnel.
Written informed consent will be obtained by person-to-person contact. The research staff
will be responsible for the informed consent.

Subjects who agree to participate in the study will be randomized to one of the two groups
below in a 1/1 allocation:

- Standard Wound Care: Wound dressing and care as per our current practice. Compression
dressing consisting of gauze, tefla and adhesive tape will be placed intraoperatively.
Dressing will be removed after 24 hours from surgery completion and subjects will have
an absorption pad with overlying garments for the remaining postoperative days until
standard postoperative visit for wound check.

- CHG Wound Care: ReliaTect™ Post-Op Dressing will be applied as per the manufacturer's
instructions (Appendix A) intraoperatively. The dressing will be in place until the
postoperative clinic visit on postoperative day 7.

The remainder of the subjects' care will be similar for both arms and will follow current
standard clinical practice at the University of Texas Medical Branch (UTMB).

Inclusion Criteria:

- 18-50 years of age.

- Women ≥ 24 weeks' viable gestation.

- To undergo cesarean delivery.

- Admission BMI ≥ 35.

Exclusion Criteria:

- Patient unwilling or unable to provide consent.

- No prenatal care or a non-resident patient who is unlikely to be followed-up after
delivery.

- Immunosuppressed subjects: i.e., taking systemic immunosuppressant or steroids (e.g.
transplant subjects; not including steroids for lung maturity), HIV with CD4 <200, or
other.

- Decision not to have skin closure (e.g. secondary wound closure, mesh closure).

- Current skin infection.

- Coagulopathy.

- High likelihood of additional surgical procedure beyond cesarean (e.g. scheduled
hysterectomy, bowel or adnexal surgery).

- Known allergy to CHG.

- Incarcerated individuals.

- Chorioamnionitis.

- Subjects participating on other treatment trials or studies that would interfere with
the current study's primary outcome.